Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 119.97

-2.9%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	1/25/2006 8:30:25 AM
	Read Replies (1) of 276

01/23/06 11:04 am EST... S&P DOWNGRADES SHARES OF ILLUMINA TO HOLD FROM BUY (ILMN 19.95***): ILMN shares have risen over 40% this year. Although we believe the company is gaining market share, we see challenges in capital equipment sales in the first half of 2006, as we see continued tight capital budgets. In spite of these challenges, and ahead of the company’s Q4 release, we think ILMN will report an installed base of about 122 systems, a strong increase in consumable sales and a robust market for genotyping services. We see breakeven results. Our 12-month target price rises by $4 to $22, based on revised DCF analysis. /J.Loo-CFA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next